Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.65 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 9/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164735 | 1.00 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL27994035 | 0.98 | NCF1 (0.63) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL30760998 | 0.81 | NCF1 (0.71) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL10458402 | 0.81 | NCF1 (0.71) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL5806618 | 0.79 | NCF1 (0.68) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL5506476 | 0.79 | NCF1 (1.00) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL4937771 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL6645329 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL4937770 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A | |
| SCHEMBL22593292 | 0.77 | NCF1 (0.65) | NCF1NOS2BACE1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744676-A2 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | Synlogic Operating Company, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3882259-B1 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | SYNLOGIC OPERATING CO INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12409195-B2 | Bacteria engineered to reduce hyperphenylalaninemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4103946-B1 | IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME | IMMUNDIAGNOSTIK AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-20240076645-A1 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | SYNLOGIC INC. | 2024-03-07 | — | — | US | disclosed |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-116908277-A | Application of 2-hydrazinoquinoline as matrix in MALDI-MS analysis of body fluid | 中国科学院化学研究所 | 2023-10-20 | — | — | CN | disclosed |
| US-11685925-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230109016-A1 | IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME | IMMUNDIAGNOSTIK AG (DE) | 2023-04-06 | — | — | US | disclosed |
| US-11618894-B2 | Bacteria engineered to reduce hyperphenylalaninemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230043588-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4103946-A1 | IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME | Immundiagnostik AG (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4095150-A1 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | Synlogic Operating Company, Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220226395-A1 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES | SYNLOGIC OPERATING COMPANY, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11384359-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | SYNLOGIC OPERATING COMPANY, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3988107-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | Synlogic Operating Company, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3377518-B1 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | SYNLOGIC OPERATING CO INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11291693-B2 | Bacteria engineered to treat metabolic diseases | SYNLOGIC OPERATING COMPANY, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291693-B2 | Bacteria engineered to treat metabolic diseases | GOT2, BPGM, MLYCD | NCF1 3459/4885NOS2 1609/4885BACE1 1626/4885 |
| US-11384359-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | FABP2, TLR9, LY96 | NCF1 1362/4885NOS2 488/4885BACE1 3635/4885 |
| US-20230043588-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | FABP2, TLR9, LY96 | NCF1 1362/4885NOS2 488/4885BACE1 3635/4885 |
| US-11618894-B2 | Bacteria engineered to reduce hyperphenylalaninemia | PAH, HMBS, TYR | NCF1 3565/4885NOS2 1047/4885BACE1 3896/4885 |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | FABP2, TLR9, LY96 | NCF1 1362/4885NOS2 488/4885BACE1 3635/4885 |
| US-12409195-B2 | Bacteria engineered to reduce hyperphenylalaninemia | PAH, HMBS, TYR | NCF1 3565/4885NOS2 1047/4885BACE1 3896/4885 |
| US-11685925-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | FABP2, TLR9, LY96 | NCF1 1362/4885NOS2 488/4885BACE1 3635/4885 |
| US-20240076645-A1 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | PAH, HMBS, TYR | NCF1 3565/4885NOS2 1047/4885BACE1 3896/4885 |
| US-20220226395-A1 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES | GOT2, BPGM, MLYCD | NCF1 3459/4885NOS2 1609/4885BACE1 1626/4885 |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | GOT2, BPGM, MLYCD | NCF1 3459/4885NOS2 1609/4885BACE1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.